---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031188"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:00:23.905527+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q1 revenue up 4.9% to $12.9M; net loss widens to $59K

## Summary
- Revenue $12.9M vs $12.3M YoY, a 4.9% increase.
- Operating loss of $54K vs operating income of $30K in prior year.
- Net loss of $59K ($0.00 per share) vs net loss of $35K ($0.00 per share).
- Two largest customers represent 91% of Q1 revenue in Contract Manufacturing Segment.
- Co-CEOs cite revenue growth from top customers.

## SEC filing metadata
- accession: 0001437749-23-031188
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774923031188/0001437749-23-031188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774923031188/inbp20231107_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031188
- JSON: https://secwatch.observer/filing/0001437749-23-031188.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031188.txt

## Key facts
- Earnings Releases
  INTEGRATED BIOPHARMA INC reported the quarter ended September 30, 2023 results: revenue $12.9 million, net income net loss of approximately $59,000 or $0.00 per share, EPS $0.00 per share of common stock.
  - Period: the quarter ended September 30, 2023
  - Revenue: $12.9 million
  - Net income: net loss of approximately $59,000 or $0.00 per share
  - EPS: $0.00 per share of common stock
  - Result: reported results
  source text: Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended September 30, 2023. Revenue for the quarter ended September 30, 2023 was $12.9 million compared to $12.3 million for the quarter ended September 30, 2022, an increase of $0.6 million or approximately 4.9%. The Company had an operating loss for the quarter ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774923031188/0001437749-23-031188-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.